The shares of UnitedHealth (UNH) are currently undervalued when using optimistic estimates. However, even with slightly conservative estimates, the current share price could still provide a 9% annual return potential from this moment onwards.
A majority of investors are more likely interested in how the valuation and possible long-term return for a specific stock look like. Let us start with valuation first. I will not be delving into the current business situation of UnitedHealth as there are already plenty of excellent articles covering this topic. Personally, I prefer to keep my estimates as conservative as possible in order to avoid negative surprises. In the case of UnitedHealth, if we were to assume the historical 10-year annual revenue growth of 10.0% and free cash flow to sales ratio of 5.2% could be sustained in the future, we would arrive at a normalized free cash flow level worth $11,823 million. With the current amount of outstanding shares, this translates into roughly $12.4 per share. Just as a reference, the 20-year historical values for the annual revenue growth and FCF to sales have been 16.3% and 6.3%, respectively. For 2017, analysts are expecting free cash flow per share of around $10.25 per share, which is much more pessimistic than mine.
Top 5 Undervalued Stocks To Buy For 2018: Old Second Bancorp Inc.(OSBC)
- [By Lisa Levin]
Friday afternoon, the financial sector proved to be a source of strength for the market. Leading the sector was strength from Wins Finance Holdings Inc (NASDAQ: WINS) and Old Second Bancorp Inc. (NASDAQ: OSBC).
Top 5 Undervalued Stocks To Buy For 2018: Medtronic plc(MDT)
- [By Ben Levisohn]
US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.
- [By ]
Medical device makers will also be in the price-control crosshairs. If the government can mandate drug prices, the same can be expected for pacemakers, artificial joints and other devices. Companies such as Medtronic (NYSE: MDT) and previously mentioned pharma giant Johnson & Johnson will find themselves adjusting to a new paradigm.
- [By James E. Brumley]
When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.
General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.
Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.
The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.
Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It
- [By Ben Levisohn]
Cardinal Health (CAH) tumbled to the bottom of the S&P 500 today after agreeing to buy Medtronic’s (MDT) medical supplies business for $6.1 billion and offering disappointing guidance.
Top 5 Undervalued Stocks To Buy For 2018: CIRCOR International, Inc.(CIR)
- [By Lisa Levin]
CIRCOR International, Inc. (NYSE: CIR) was down, falling around 15 percent to $60.91. CIRCOR reported Q4 adjusted earnings of $0.48 per share on revenue of $158 million. Stifel Nicolaus downgraded Circor from Buy to Hold.
Top 5 Undervalued Stocks To Buy For 2018: Silver Bay Realty Trust Corp.(SBY)
- [By Lisa Levin]
Shares of Silver Bay Realty Trust Corp (NYSE: SBY) got a boost, shooting up 18 percent to $21.47. Tricon Capital Group Inc. announced plans to buy Silver Bay Realty Trust for $21.50 per share.
- [By Mark Holder]
Instead of competing in one-off auctions, the traditional method of acquiring homes and the one preferred by Silver Bay Realty Trust (NYSE: SBY ) (NYSE: SBY ) (NYSE: SBY ) and American Homes 4 Rent (NYSE: AMH ) (NYSE: AMH ) (NYSE: AMH ) , the company is obtaining non-performing loans in pools that include thousands of loans. The ultimate outcome of these different models is unknown, but the market hasso far supported Altisource Residential.
Top 5 Undervalued Stocks To Buy For 2018: Pound/Rand(PX)
- [By Ben Levisohn]
The last twelve months haven’t been kind to Praxair (PX) and Air Products & Chemicals (APD), but UBS analyst John Roberts and team argue that’s about to change, as they upgrade their shares to Buy from Neutral arguing that their earnings can withstand a slowing global economy:
In our view, the two stocks are more alike than different. NTM P/Es are within ~0.5 pts of each other. Both stocks have declined ~20% from their historical highs the largest corrections in 20+ years aside from the financial crisis…
Industrial gas stocks have normally grown through changes in FX, oil & China demand within normal historical ranges. And investor concerns around China forAir Products & Chemicals may still prove much bigger than reality. Nevertheless, the combination of FX & oil sector impacts on Praxair, and FX & China issues for Air Products & Chemicals, have been much larger than previously seen. With oil already down, the dollar already appreciated, & China concerns already heightened we believe forward basis would appear to carry only normal risks (& lower if FX & oil are mean-reverting, which some theories support).
Normal high single digit EPS growth projected for both in 2017 vs 2016: Four large firms serve 70%+ of the global merchant gas market, and price normally contributes ~2% to growth. Customer older captive units being outsourced contributes another 2%. Secular drivers for oxygen include energy savings (i.e. O2 burns more efficiently than air), life sciences (healthcare & microbial processes) nitrogen secular drivers include increasing purity requirements (food freezing & semiconductors). Topline growth ~2x global GDP more normal, with EPS growth ~2x sales growth due to high fixed costs (key variable costs are inexpensive air & power).
Financial crisis demand drop was only a few %, in line with global GDP drop Most chemicals volumes dropped 10%+ (some 40%